5.5 is Marrone Bio Innovations Inc’s (NASDAQ:MBII) Institutional Investor Sentiment

June 20, 2018 - By Peter Erickson

Marrone Bio Innovations, Inc. (NASDAQ:MBII) Logo

Sentiment for Marrone Bio Innovations Inc (NASDAQ:MBII)

Marrone Bio Innovations Inc (NASDAQ:MBII) institutional sentiment increased to 5.5 in Q1 2018. Its up 4.93, from 0.57 in 2017Q4. The ratio is positive, as 11 hedge funds opened new and increased equity positions, while 2 sold and reduced stock positions in Marrone Bio Innovations Inc. The hedge funds in our partner’s database now have: 78.12 million shares, up from 11.74 million shares in 2017Q4. Also, the number of hedge funds holding Marrone Bio Innovations Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 1 Reduced: 1 Increased: 5 New Position: 6.

Marrone Bio Innovations, Inc. provides bio pest management and plant health products primarily for agricultural and water markets in the United States and internationally. The company has market cap of $199.95 million. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation. It currently has negative earnings. The companyÂ’s products include Regalia, a plant extract fungicidal biopesticide for plant disease control and plant health; and Grandevo, a bioinsecticide for insect and mite control to the growers of specialty crops, such as grapes, citrus, tomatoes, vegetables, nuts, leafy greens, and ornamental plants.

The stock decreased 0.55% or $0.01 during the last trading session, reaching $1.81. About 329,561 shares traded. Marrone Bio Innovations, Inc. (NASDAQ:MBII) has risen 48.33% since June 20, 2017 and is uptrending. It has outperformed by 35.76% the S&P500.

Analysts await Marrone Bio Innovations, Inc. (NASDAQ:MBII) to report earnings on August, 13. They expect $-0.04 earnings per share, up 84.00 % or $0.21 from last year’s $-0.25 per share. After $-0.04 actual earnings per share reported by Marrone Bio Innovations, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Ardsley Advisory Partners holds 1.91% of its portfolio in Marrone Bio Innovations, Inc. for 10.35 million shares. Waddell & Reed Financial Inc owns 24.71 million shares or 0.11% of their US portfolio. Moreover, Capital Planning Advisors Llc has 0.02% invested in the company for 33,079 shares. The North Carolina-based Bank Of America Corp De has invested 0% in the stock. Barclays Plc, a United Kingdom-based fund reported 20,200 shares.

Since January 1, 0001, it had 1 insider purchase, and 0 sales for $5.00 million activity.

More important recent Marrone Bio Innovations, Inc. (NASDAQ:MBII) news were published by: Investorideas.com which released: “Investor Ideas #Potcasts: #Cannabis News and Stocks on the Move; (CSE: $BE.C), (TSXV:$RLV.V), (NASDAQ: $MBII …” on June 04, 2018, also Nasdaq.com published article titled: “Marrone Bio Innovations’ Amplitudeâ„¢ Biofungicide is Available for This Growing Season’s Fight Against White Mold”, Globenewswire.com published: “Marrone Bio Innovations, Inc. to Present at 8th Annual LD Micro Invitational Investor Conference in Los Angeles” on May 25, 2018. More interesting news about Marrone Bio Innovations, Inc. (NASDAQ:MBII) was released by: Nasdaq.com and their article: “Mid-Morning Market Update: Markets Edge Higher; Navistar Profit Tops Expectations” with publication date: June 05, 2018.

Marrone Bio Innovations, Inc. (NASDAQ:MBII) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: